Treatment of Cogan's Syndrome with Anti-TNF Biologic Therapy
This protocol addresses the management of Cogan's syndrome using biologic therapy, with anti-TNF agents forming the primary focus of the evidence base.
Current evidence supports anti-TNF biologic therapy — used either alone or in combination with conventional immunomodulatory agents — as the key treatment approach; the full protocol specifies agents, combinations, and clinical decision points beyond this summary.
References
DOI: 10.1016/j.revmed.2024.09.007
- More recently, anti-TNFα agents, particularly infliximab, have been offered in addition to steroid therapy, either alone or in combination with disease-modifying antirheumatic drugs (DMARDs).
- Data on other biologic therapies is even more limited; five isolated cases report the efficacy of tocilizumab, and two cases of rituximab.
- Combination with anti-TNF therapy should be promptly discussed.
View source ↗